-- マレーシアは4月30日から、補助金対象外のRON95とRON97ガソリンの価格を引き上げる。これは過去2週間続いた価格下落に終止符を打つものだと、FMTは水曜日に財務省の発表を引用して報じた。 RON95は1リットルあたり0.10リンギット値上げされ3.97リンギット、RON97は1リットルあたり0.05リンギット値上げされ4.90リンギットとなる。マレー半島におけるディーゼル価格は1リットルあたり5.12リンギットで据え置かれる。 補助金対象燃料の価格は据え置かれ、BUDI95制度におけるRON95は1リットルあたり1.99リンギット、サバ州、サラワク州、ラブアン島におけるディーゼル価格は2.15リンギットで維持される。SKPSやSKDSなどのその他の補助金制度も、5月6日まで据え置かれると報じられている。 同省は、中東の施設損傷による供給途絶のため、世界の原油価格は高止まりしていると述べた。同省は燃料の慎重な使用を呼びかけ、政府はエネルギー価格上昇が消費者に与える影響を軽減するために引き続き取り組んでいくと付け加えた、と報道機関は伝えた。 （マーケットチャッターのニュースは、世界中の市場専門家との会話に基づいています。この情報は信頼できる情報源に基づいていると考えられますが、噂や憶測が含まれる可能性があります。正確性は保証されません。）
Related Articles
Research
Research Alert: Blue Owl Capital Reports Slight Distributable Earnings Beat And Aum Growth
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:OWL delivered Q1 2026 FRE of $0.25 vs $0.23 consensus and DE of $0.19 vs $0.18 consensus, with LTM FRE revenues up 13% and FRE up 14% Y/Y. AUM rose 15% Y/Y to $315B though sequential growth was limited by redemptions, while fee-paying AUM reached $188B, up 7% Y/Y. We believe OWL is well-positioned for the secular shift to private credit and is diversifying beyond its leading credit position across multiple debt financing categories. Management noted software loan balances represent only 8% of total AUM, addressing market concerns, but provided no specific financial guidance. The annual dividend increased 25% Y/Y to $0.90 per share in 2025, and the company repurchased 1.7M shares for $25M in Q1 2026. We expect positive AUM trends to continue as new capital raised was more than double fund distributions. Despite share price volatility from direct lending concerns, we would stay the course with OWL shares given strong fundamentals.
$OWL
Research
Research Alert: Bax Q1: Mixed Results Amid Operational Challenges And Transformation Efforts
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Baxter delivered mixed Q1 2026 results with sales of $2.7B (+3% reported, -1% organic) beating consensus by $80M, though organic decline highlighted execution issues. Adjusted EPS of $0.36 beat expectations by $0.05 but declined 35% Y/Y due to unfavorable expense timing and higher manufacturing costs. We view the persistent operational challenges across key divisions as concerning despite management's transformation efforts. Management reiterated full-year 2026 guidance of flat to 1% sales growth and adjusted EPS of $1.85-$2.05, emphasizing progress on the Baxter Growth and Performance System with 230+ Q1 initiatives. Segment performance remained mixed with Medical Products & Therapies generating $1.3B (+2% reported, -2% organic) hampered by infusion pump issues, while Pharmaceuticals provided strength at $621M (+7% reported). We believe the ongoing execution challenges underscore the complexity in stabilizing operations despite improved free cash flow of $76M vs. -$221M in the prior year.
$BAX
Research
Research Alert: Blue Owl Capital Reports Slight Distributable Earnings Beat And Aum Growth
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:OWL delivered Q1 2026 FRE of $0.25 vs $0.23 consensus and DE of $0.19 vs $0.18 consensus, with LTM FRE revenues up 13% and FRE up 14% Y/Y. AUM rose 15% Y/Y to $315B though sequential growth was limited by redemptions, while fee-paying AUM reached $188B, up 7% Y/Y. We believe OWL is well-positioned for the secular shift to private credit and is diversifying beyond its leading credit position across multiple debt financing categories. Management noted software loan balances represent only 8% of total AUM, addressing market concerns, but provided no specific financial guidance. The annual dividend increased 25% Y/Y to $0.90 per share in 2025, and the company repurchased 1.7M shares for $25M in Q1 2026. We expect positive AUM trends to continue as new capital raised was more than double fund distributions. Despite share price volatility from direct lending concerns, we would stay the course with OWL shares given strong fundamentals.
$OWL